Literature DB >> 34779987

The role of Wnt pathway antagonists in early-stage lung adenocarcinoma.

Arife Zeybek1, Necdet Öz2, Serdar Kalemci3, Kürşad Tosun4, Tuba Gökdoğan Edgünlü5, Mehmet Tuğhan Kızıltuğ6, Leyla Tekin7, Mehmet Emin Erdal6.   

Abstract

PURPOSE: We aimed to examine the expression levels of the genes encoding adenomatous polyposis coli (APC) 1, APC-2, Dickkopf related protein (DKK)-1, DKK-3, secreted frizzled-related protein (SFRP)-2, SFRP-4, and SFRP-5, which play roles in the Wnt signaling pathway, in lung adenocarcinoma and adjacent normal lung tissues and to evaluate their relationships with clinicopathologic factors.
MATERIALS AND METHODS: The expression levels of genes in formalin-fixed paraffin-embedded samples of tumor tissue and adjacent intact lung tissue from 57 patients who underwent surgery for lung adenocarcinoma between 2011 and 2018 were determined by real-time PCR analysis.
RESULTS: The expression levels of the DKK-1 in tumor tissue, especially in stage I-II tumor tissue, were significantly suppressed compared to those in normal tissue (p < 0.025). Whereas DKK-1 expression was suppressed in the tumor tissue of patients with early-stage lung adenocarcinoma, expression of the SFRP-5 in these patients was significantly higher in tumor tissue than in normal tissue (p < 0.039).
CONCLUSION: In our study, opposing regulation was found between the SFRP-5 and DKK-1, which are known to be extracellular antagonists of the Wnt signaling pathway. The SFRP-5 was found to have an oncogenic role in adenocarcinoma development. Studies of the opposing regulation between these genes in early-stage lung adenocarcinoma may shed light on the mechanisms associated with the development of carcinogenesis. The relationships or interactions of these genes may serve as potential therapeutic targets.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  APC-1 gene; APC-3 gene; DKK-1 gene; DKK-3 gene; Lung adenocarcinogenesis; SFRP proteins

Mesh:

Substances:

Year:  2021        PMID: 34779987     DOI: 10.1007/s11033-021-06759-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  8 in total

Review 1.  Wnt signaling in disease and in development.

Authors:  Roel Nusse
Journal:  Cell Res       Date:  2005-01       Impact factor: 25.617

Review 2.  Wnt genes.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

Review 3.  Towards an integrated view of Wnt signaling in development.

Authors:  Renée van Amerongen; Roel Nusse
Journal:  Development       Date:  2009-10       Impact factor: 6.868

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Wnt proteins are lipid-modified and can act as stem cell growth factors.

Authors:  Karl Willert; Jeffrey D Brown; Esther Danenberg; Andrew W Duncan; Irving L Weissman; Tannishtha Reya; John R Yates; Roel Nusse
Journal:  Nature       Date:  2003-04-27       Impact factor: 49.962

Review 6.  Beta-catenin: a key mediator of Wnt signaling.

Authors:  K Willert; R Nusse
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

7.  Pan-cancer methylation and expression profiling of adenocarcinomas revealed epigenetic silencing in the WNT signaling pathway.

Authors:  J Li; K L Huang; T Zhang; H Li; J Zhao; H Wang
Journal:  Neoplasma       Date:  2016       Impact factor: 2.575

8.  Integrated Network Analysis Reveals FOXM1 and MYBL2 as Key Regulators of Cell Proliferation in Non-small Cell Lung Cancer.

Authors:  Firoz Ahmed
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

  8 in total
  1 in total

1.  A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.

Authors:  Yinliang Lu; XueHui Luo; Qi Wang; Jie Chen; Xinyue Zhang; YueSen Li; Yuetong Chen; Xinyue Li; Suxia Han
Journal:  Front Genet       Date:  2022-03-17       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.